INSIGHTS ON EMERGING CAR T THERAPIES

With evidence showing that the scavenger receptor CD5 inhibits chimeric antigen receptor (CAR) T-cell activation, investigators believe that CD5 knockout is the key to improving the clinical...

A retrospective study concluded that idecabtagene vicleucel (ide-cel) works as safely and effectively in older patients with multiple myeloma (MM) as in younger adults, despite a greater presence...

In a multicenter study, researchers have initiated a first-in-human phase 1, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, aimed at treating...

Results of a single-site analysis suggest that despite emerging concern over the potential for secondary tumors and T-cell lymphoma following chimeric antigen receptor (CAR) T-cell infusion, such...

Chimeric antigen receptor(CAR)-engineered natural killer (NK) cells designed with a CD28 costimulatory domain have superior anti-tumor efficacy and long-term cytotoxicity, research indicates.

Researchers from the Centre de Recherche Saint-Antoine (CRSA) at Sorbonne Université in France investigated the impact of early recovery of mucosal-associated invariant T (MAIT) cells and...